All In Biotech

Drug Trial Radar · NCT05319353

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 13, 2023

Primary completion

Jan 18, 2027

Study completion Jan 18, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Apr 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of maribavir using a 200 milligrams (mg) tablet formulation or powder for oral suspension. The participants will be treated with maribavir for 8 weeks. Participants need to visit their doctor during 12-week follow-up period.

Conditions

  • Cytomegalovirus (CMV)

Interventions

  • MaribavirDrug

    Participants will receive maribavir.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of MaribavirTime frame: Pre-dose; 0.5, 1.5, 3, 4, 6, and 8 hours post-dose on Day 7 (Week 1)
  2. Time to Maximum Observed Concentration (Tmax) of MaribavirTime frame: Pre-dose; 0.5, 1.5, 3, 4, 6, and 8 hours post-dose on Day 7 (Week 1)
  3. Minimum Plasma Concentration (Cmin) of MaribavirTime frame: Pre-dose; (0.5, 1.5, 3, 4, 6, and 8 hours post-dose) on Day 7 (Week 1); Pre-dose on Day 28 (Week 4); Pre-dose; (2 to 4 hours post-dose) on Day 56 (Week 8)
  4. Area Under the Plasma Concentration-Time Curve Over the 1 Dosing Interval of 12 Hours at Steady State (AUC0-tau) of MaribavirTime frame: Pre-dose; 0.5, 1.5, 3, 4, 6, and 8 hours post-dose on Day 7 (Week 1)
  5. Half-Life (t1/2) of MaribavirTime frame: Pre-dose; 0.5, 1.5, 3, 4, 6, and 8 hours post-dose on Day 7 (Week 1)
  6. Terminal Elimination Rate Constant (lambdaz) of MaribavirTime frame: Pre-dose; 0.5, 1.5, 3, 4, 6, and 8 hours post-dose on Day 7 (Week 1)
  7. Apparent Volume of Distribution (Vz/F) of MaribavirTime frame: Pre-dose; 0.5, 1.5, 3, 4, 6, and 8 hours post-dose on Day 7 (Week 1)
  8. Apparent Oral Clearance (CL/F) of MaribavirTime frame: Pre-dose; 0.5, 1.5, 3, 4, 6, and 8 hours post-dose on Day 7 (Week 1)
  9. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From start of study drug administration up to follow-up (Week 20)

Locations

53 sites in 11 countries. Site status is shown where the registry gives one.

  • Nemours Children's Health - Wilmington - PIN

    Wilmington, Delaware · Recruiting

  • Johns Hopkins All Children's Hospital - Main - PIN

    St. Petersburg, Florida · Recruiting

  • Ann and Robert H Lurie Childrens Hospital of Chicago - PIN

    Chicago, Illinois · Recruiting

  • University of Nebraska Medical Center -985400 Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Cincinnati Children's Hospital Medical Center - PIN

    Cincinnati, Ohio · Recruiting

  • Cook Children's Health Care System

    Fort Worth, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center - 1515 Holcombe Blvd

    Houston, Texas · Recruiting

  • Texas Children's Hospital - Wallace Tower - PIN

    Houston, Texas · Recruiting

  • Minderoo Children's Comprehensive Cancer Centre

    Randwick, New South Wales, Australia · Recruiting

  • Queensland Children's Hospital

    Woollangabba, Queensland, Australia · Recruiting

  • Royal Children's Hospital Melbourne - PIN

    Parkville, Victoria, Australia · Recruiting

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia · Recruiting

  • Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)

    Brussels, Brussels Capital, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Brussels Capital, Belgium · Recruiting

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Hospital Do Rim E Hipertensão

    São Paulo, Brazil · Recruiting

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Capital Center For Children's Healthy, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Children's Hospital, Capital Medical University - PIN

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital, Sun Yat-sen University - Main

    Guangzhou, Guangdong, China · Recruiting

  • Shenzhen Children's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Shanghai Children's Medical Center - Zhangjiang Campus

    Shanghai, Shanghai Municipality, China · Recruiting

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences - PPDS

    Tianjin, Tianjin Municipality, China · Recruiting

  • Hopital Necker

    Paris, France · Recruiting

  • CHU de Rennes - Hôpital Pontchaillou

    Rennes, Ille-et-Vilaine, France · Recruiting

  • CHU de Grenoble Alpes - Hôpital Michallon

    La Tronche, Isère, France · Recruiting

  • CHRU Nantes

    Nantes, Loire-Atlantique, France · Recruiting

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Recruiting

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, Germany · Recruiting

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, Germany · Recruiting

  • Universitatsklinikum Jena - Am Klinikum 1-Erlanger Allee 101

    Jena, Thuringia, Germany · Recruiting

  • Rambam Health Care Campus - PPDS

    Haifa, Israel · Recruiting

  • Hadassah Medical Center- Ein Kerem - PPDS

    Petah Tikva, Israel · Recruiting

  • The Chaim Sheba Medical Center - PPDS

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center Ichilov - PPDS

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • Hyogo Prefectural Kobe Children's Hospital

    Chiba, Japan · Recruiting

  • Osaka Women's and Children's Hospital

    Izumi-Shi, Ôsaka, Japan · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.